Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 9 December 2014, 13:00 HKT/SGT
Share:
    

Source: PT Bio Farma (Persero)
Bio Farma Rolls Out Pentavalent Vaccine to All Provinces of Indonesia in 2014

JAKARTA, Dec 9, 2014 - (ACN Newswire) - The Indonesian Ministry of Health introduced Bio Farma's Pentavalent vaccine into the immunization program in 2013, and in 2014 rolled the vaccine out across the 33 provinces of the vast archipelago. Administered to infants 2 months to 1 year old, the vaccine protects against five infectious diseases, including Diphtheria, Tetanus, Pertussis, Hepatitis B (HB) and Haemophilus Influenzae type B (HIB).

Rahman Rustan, Corporate Secretary of Bio Farma, said the Pentavalent vaccine is the result of extensive vaccine development since 2007, involving five antigens namely Diphtheria, Pertussis, Tetanus, Hepatitis B (DPT-HB) and Haemophilus Influenzae type B vaccines.

The combination of the five antigens is possible due to a similar immunization schedule for the five antigens given to infants 2, 3 and 4 months of age. Consequently, the infants will be given Pentavalent shots at these 3 intervals each containing the five antigens.

Rustan suggested Pentavalent vaccine would undoubtedly increase affordability. Besides reducing the frequency of injections given to infants, Pentavalent vaccine is more efficient and eco-friendly. "Pentavalent vaccine is expected to reduce the number of needles required for administration as well as the cold storage required, not to mention it is environmentally-friendly through reducing waste."

Clinical Trial

Dr. Novilia S. Bachtiar, Clinical Trial and Surveillance Senior Manager of Bio Farma, added that clinical trials for the Pentavalent vaccine have been conducted since 2010, and the vaccine has successfully passed a Phase III clinical trial. The trial was conducted in collaboration with Hasan Sadikin Hospital / Medical Faculty of Pajajaran University and Cipto Mangunkusumo Hospital / Medical Faculty of University of Indonesia.

Pentavalent vaccine has been registered with the National Agency for Drug & Food Control (NADFC), and approved accordingly. "In 2013, Pentavalent vaccine was supplied to four provinces, including West Java, Bali, NTB and Yogyakarta, while in 2014 to all 33 provinces of Indonesia," said Dr. Bachtiar.

Bio Farma predicted that demand for Pentavalent vaccine in Indonesia will reach 15 million doses per year. This prediction is based on the average birth cohort in Indonesia of 5 million a year. Beside fulfillment of domestic demand, Bio Farma also plans to export Pentavalent to other countries, after the vaccine has acquired WHO prequalification, anticipated by early 2015.

Rotavirus vaccine Clinical Trial

A Rotavirus vaccine (vaccine for diarrhoeal infection) clinical trial is currently being conducted (phase IIB trial), since January 2013, in collaboration with the Faculty of Medicine, University of Gadjah Mada, involving approximately 1600 infants in Yogyakarta and Central Java.


Contact:
N.Nurlaela
Corporate Communications Manager
PT Bio Farma (Persero)
Tel: +62 22 2033755
Fax: +62 22 2041306
E-mail: corcom@biofarma.co.id


Topic: New market for product
Source: PT Bio Farma (Persero)

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



PT Bio Farma (Persero)
Oct 4, 2022 07:00 HKT/SGT
Bio Farma secures Multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)
Sept 30, 2022 18:00 HKT/SGT
Bio Farma to Export its Polio Vaccine After Securing Purchase Contracts from UNICEF for 2022 and 2023
Sept 13, 2022 06:40 HKT/SGT
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines
Sept 9, 2022 17:00 HKT/SGT
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
May 1, 2015 14:00 HKT/SGT
9th International Conference on Typhoid, Invasive NTS Disease Held in Bali, Indonesia
Dec 5, 2014 19:00 HKT/SGT
Bio Farma Continues Presidency of the Developing Country Vaccine Manufacturers Network (DCVMN)
Dec 4, 2014 18:00 HKT/SGT
Bio Farma Awarded Gold PROPER by the Indonesian Ministry Of Environment & Forestry
Oct 23, 2013 16:30 HKT/SGT
Indonesia as the Hub of Excellence for Biological Products for Islamic Countries
Aug 24, 2013 12:00 HKT/SGT
Bio Farma Launches Pentavalent Vaccine, Combining Five Antigens
July 2, 2013 21:00 HKT/SGT
Bio Farma Holds Third Indonesian Vaccine Research Forum
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: